Member Info for BOJO2020

Exactly Mia thanks. 927 million shares in issue so I guess that is it? Dont get me wrong I would prefer 200 million but obviously not the case. I did see someone mentioned that Scancell would have 1.2 billion shares in issue following the raise but guess that is wrong or am I missing something?

An unconditional Happy Christmas to everyone!

Reminiscent of the old Monty Python sketch…

Is this a dead parrot? Ceased to be? Has it fallen off this mortal coil?

🤔

Hi TF,

Balance on my investment platforms today indicates that I have been debited for the open offer. I am expecting an RNS Tuesday 19th. Slightly curious to see which direction the SP goes up until Friday but for me it is all about Jan when the market steps into a more regular rhythm.

Good points raised by Inan, Burble, and excellent questions from RR. Nice to be cashed up as you say with a good trajectory for SCIB1. Really looking for iSCIB1+ to work out which is not a given and also durable response is my main focus now.

MM are simply undercutting the OO. They see a an oppurtunity I suppose.

I have been buying in the open market and my allocation in OO. Cheap either way

We know that cancer can evade the immune system and that in such instances when drugs are used, especially novels ones, cancer seems especially adept at evading them. So you could say that with a cancer that is smart enough to seed, it is little wonder that it can evade drugs.

So, my question is this. SCIB1 is demonstrating success in several types of outcome measures including ORR and tumour burden. Granted, it must demonstrate a durable response, but why is it successful so far? Reminder the expected outcomes for novel drugs is extremely poor.

Many thanks in advance

RR,

I did like the way in which you have answered RP's question. All though the question itself is a bit tongue in cheek to be sure you have recognised that Immunobody has a value (as Ray asked) and you have translated it into the overall share price. Maybe the values are debatable but quite an interesting method you use, especially over time. Thanks.

Weds 6th and no sign of OO on interactive so far. But I managed to top up at 11.19 the other day

Tom,

You seem very emotional. My 8.09 and 8.14 are aimed for TGTD. He is suggesting that it was an RNS when the actual RNS states that it is a Reach no regulatory RNS. Have you actually read the RNS? Because I copied and pasted my 8.14 from the news feed.

And they need to read the news properly. It clearly states several paragraphs down:

"This information is provided by Reach, the non-regulatory press release distribution service of RNS."

Nonrns...

Although tissue biopsy is superior too ctDNA liquid biopsy (study of fragments of dead cancer cells) because RNA, DNA, Protein expression can be analysed vs just DNA, it is a one time only. So arguably that puts ctDNA liquid biopsy ahead as it is repeatable and can provide up to date information. My thoughts have been that as Parsortix lacked assays and more importantly a kit to make it usable, it was behind both ctDNA and tissue biopsy. With today's announcement, Angle have put themselves in the game. They have the best of both worlds. Full expression can be analysed and it is repeatable.

The terms and conditions of the Open Offer will be set out in the Circular to be sent to Qualifying Shareholders and (for information only) to Excluded Overseas Shareholders who have notified an address in the United Kingdom for the service of documents in accordance with the Articles. It is expected that the Circular will be dispatched on or around 4 December 2023, and will also be available at this time on the Company's website at www.scancell.co.uk. Further information about the Company and the Capital Raise, including, inter alia, the expected timetable of principal events is set out in Appendix I. Capitalised terms not otherwise defined in the text of this announcement are defined in Appendix IV.

From Thursdays RNS.

I expect a notification on my investment platform so will look out for that. Or visit Scancell website

Not whinging but the one for every forty five shares probably means there will not be many spare shares imo. Unless you all hold millions of shares?!

The last couple of times Scancell raised the share price took off. Also worth pointing out that Scancell have clearly indicated the direction of travel and they appear to have the means to execute its plans. Think the market will be satisfied with this very muchley in the not to distant.

Correct me if I am wrong

Open offer, any qualifying shareholder will be able to apply for one share for every forty five they hold.

Open offer, Scancell will initiate contact Monday 4th December 23

Shares from the placing / subscription of £10.7m are to be submitted AIM at 8am Tuesday 5th December.

So it is possible that submission of the placing and subscription shares (97m) will have an impact on the share price by Tuesday.

Shareholders will still have an option to take part in the open offer @11p until it closes (at a date to be confirmed)

Placing - large investors - funds - institutions?

Subscription - Directors?

Open Offer - Private investors?

Corrections welcome

44p for options...

TGTD,

Time for you to join team ramp. You know you want to…

TF you 14.10. I agree entirely £8m was a concern as too low. Much happier now. Maybe Scancell had an inkling of the real interest no doubt.

BTW,

Your sums seem reasonable but it is you are only factoring liabilities. Do you have a view on income too?

ATB